SYNBIO POLICY METER

BENEFITS AND COSTS

 

 

What benefits are most relevant ?

​

1. Development of innovative therapies to face intractable genetic diseases and degenerative conditions (μ=8,11; SD=1,07)

2. Development of more effective therapeutic options which are tailored on the genetic profile of patients (μ=7,79; SD=1,32)

 

 

Which stakeholders will mostly benefit ?

 

1. Private research organizations (μ=7,39; SD=1,17)

2. Patient’s organizations (μ=7,36; SD=1,31)

​

​

What costs are most relevant ?

​

1. lack of consensus and agreement within the scientific community and globally among stakeholders and the public on the legitimacy to conduct research on the genetic manipulation of human DNA (μ=7,61; SD=1,52)

2. new ethical issues concerning how these genetic modifications can be used for non- therapeutic purposes (μ=7,54; SD=1,67)

 

 

Which stakeholders will have to bear the highest costs ?

​

1. National, European and international public health agencies (μ=5,79; SD=1,52)

2. Patient organizations (μ=5,61; SD=1,34)

​

​

Which stakeholders can have a relevant role in the allocation of costs and benefits ?

​

1. Policy Makers

2. Legislators

​

​

Which procedure should be used to asses the costs and benefits of the application?

​

1. Risk Assessment Procedures

​

​

​

GOVERNANCE AND REGULATORY TOOLS

​

​

Which governance framework should be used to regulate R&D activities ?

​

1. Shared standards and international protocols (μ=7,96; SD=1,04)

​

​

Which procedure should be used to foster compliance with regulatory measures ?

​

1. Legally Binding

​

​

Which approaches are most useful in encouraging companies and research organization to comply with regulatory and governance?

​

1. Requirement to integrate the adherence to the regulatory measures into research funding through evaluation criteria (μ=7,21; SD=1,40)

2. Sanctions and penalty (μ=7,14; SD=1,84)

​

​

​

< Back to the list

​

​